Multispecific Antibody Crosslinking With UAA Covalent Target Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing proteins primarily rely on non-covalent interactions, which are often unstable and have high off-rates, limiting their effectiveness in targeted binding and therapeutic applications.
Innovation Solution
The development of conjugates with targeting domains containing unnatural amino acids (UAAs) that form covalent bonds with cell surface molecules, enhancing stability and specificity by forming covalent interactions with tumor and immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-covalent interactions are used for protein binding, then the binding is reversible and flexible, but the stability and affinity are insufficient with high off-rates
Solution Approach 1:
The patent changes the chemical nature of the binding interaction from non-covalent to covalent by incorporating unnatural amino acids with reactive groups (such as aryl-fluoro sulfate moieties) into the antibody structure. This parameter change in bond type fundamentally increases binding stability and reduces off-rates, directly resolving the contradiction between reversibility and stability.
2Reliability
If covalent bonds are formed between amino acid side chains, then binding stability increases, but the ability to form such bonds is limited except for cysteine disulfide bonds
Solution Approach 1:
The patent introduces unnatural amino acids with diverse reactive chemistries (aryl-fluoro sulfate, other electrophilic groups) at positions other than the limited cysteine disulfide bonds. This expands the parameter space of available covalent bonding options, allowing stable covalent attachment at multiple potential sites while maintaining versatility in binding target selection.
Solution Approach 2:
The patent creates a composite structure combining natural amino acids with unnatural amino acid residues containing reactive functional groups. This composite approach at the molecular level enables the protein to form stable covalent bonds with targets while retaining the structural and functional properties of natural antibodies, resolving the limitation of bond formation capability.
3Reliability
If unnatural amino acids are incorporated into targeting domains, then covalent binding capability is achieved, but the complexity of protein synthesis increases
Solution Approach 1:
The patent employs orthogonal tRNA synthetase/tRNA pairs that enable site-specific incorporation of unnatural amino acids during standard translation. This self-service mechanism allows the cell's own protein synthesis machinery to incorporate the modified amino acids without requiring external chemical modification steps, thereby reducing manufacturing complexity despite the introduction of unnatural residues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of UAAs in targeting domains stabilizes the binding of conjugates to targets, reducing off-rates and improving the efficacy of immune cell-tumor cell interactions, particularly in therapeutic contexts.
Implementation Method 1
a first targeting domain configured to bind a first target on a first cell... whereby the first targeting domain is capable of covalently binding to a first target at the site of the UAA to the first target
Data Source
AI summary
Provided herein are compositions and methods for cross-linking multi-specific antibodies to targets with conjugates. Further provided herein are conjugates comprising targeting domains, wherein the targeting domain comprises an unnatural amino acid. Further provided herein are methods of treating disease with cross-linking multi-specific antibodies.